Literature DB >> 12866986

Antiretroviral Therapy: When and What to Start-- An American Perspective.

Timothy J. Wilkin1, Roy M. Gulick.   

Abstract

The major US treatment guidelines recently recommended starting antiretroviral therapy (ART) later in the course of HIV infection due to an increasing awareness of the difficulties associated with these regimens. Most of the data to support this change come from observational cohort studies. When deciding to start ART, a number of patient-specific factors and other issues should be considered. Given the many choices for initial ART, one should individualize the choice, taking into account antiretroviral regimen potency, durability, side effects, toxicities, and convenience to ensure a sustained clinical benefit for the patient.

Entities:  

Year:  2003        PMID: 12866986     DOI: 10.1007/s11908-003-0012-z

Source DB:  PubMed          Journal:  Curr Infect Dis Rep        ISSN: 1523-3847            Impact factor:   3.663


  29 in total

1.  Viral load and heterosexual transmission of human immunodeficiency virus type 1. Rakai Project Study Group.

Authors:  T C Quinn; M J Wawer; N Sewankambo; D Serwadda; C Li; F Wabwire-Mangen; M O Meehan; T Lutalo; R H Gray
Journal:  N Engl J Med       Date:  2000-03-30       Impact factor: 91.245

2.  HIV-1 RNA, CD4 T-lymphocytes, and clinical response to highly active antiretroviral therapy.

Authors:  T R Sterling; R E Chaisson; R D Moore
Journal:  AIDS       Date:  2001-11-23       Impact factor: 4.177

3.  Close link between CD4+ and CD8+ T cell proliferation defects in patients with human immunodeficiency virus disease and relationship to extended periods of CD4+ lymphopenia.

Authors:  Scott F Sieg; Jonathan B Mitchem; Douglas A Bazdar; Michael M Lederman
Journal:  J Infect Dis       Date:  2002-04-30       Impact factor: 5.226

4.  A comparison of stavudine plus lamivudine versus zidovudine plus lamivudine in combination with indinavir in antiretroviral naive individuals with HIV infection: selection of thymidine analog regimen therapy (START I).

Authors:  K E Squires; R Gulick; P Tebas; J Santana; V Mulanovich; R Clark; B Yangco; S I Marlowe; D Wright; C Cohen; T Cooley; J Mauney; K Uffelman; N Schoellkopf; R Grosso; M Stevens
Journal:  AIDS       Date:  2000-07-28       Impact factor: 4.177

5.  A comparison of stavudine, didanosine and indinavir with zidovudine, lamivudine and indinavir for the initial treatment of HIV-1 infected individuals: selection of thymidine analog regimen therapy (START II).

Authors:  J J Eron; R L Murphy; D Peterson; J Pottage; D M Parenti; J Jemsek; S Swindells; G Sepulveda; N Bellos; B C Rashbaum; J Esinhart; N Schoellkopf; R Grosso; M Stevens
Journal:  AIDS       Date:  2000-07-28       Impact factor: 4.177

6.  Incidence of cervical squamous intraepithelial lesions in HIV-infected women.

Authors:  T V Ellerbrock; M A Chiasson; T J Bush; X W Sun; D Sawo; K Brudney; T C Wright
Journal:  JAMA       Date:  2000-02-23       Impact factor: 56.272

7.  Clinical efficacy of early initiation of HAART in patients with asymptomatic HIV infection and CD4 cell count > 350 x 10(6) /l.

Authors:  Milos Opravil; Bruno Ledergerber; Hansjakob Furrer; Bernard Hirschel; Alexander Imhof; Serge Gallant; Thomas Wagels; Enos Bernasconi; Fabian Meienberg; Martin Rickenbach; Rainer Weber
Journal:  AIDS       Date:  2002-07-05       Impact factor: 4.177

Review 8.  Antiretroviral treatment for adult HIV infection in 2002: updated recommendations of the International AIDS Society-USA Panel.

Authors:  Patrick G Yeni; Scott M Hammer; Charles C J Carpenter; David A Cooper; Margaret A Fischl; Jose M Gatell; Brian G Gazzard; Martin S Hirsch; Donna M Jacobsen; David A Katzenstein; Julio S G Montaner; Douglas D Richman; Michael S Saag; Mauro Schechter; Robert T Schooley; Melanie A Thompson; Stefano Vella; Paul A Volberding
Journal:  JAMA       Date:  2002-07-10       Impact factor: 56.272

9.  Lopinavir-ritonavir versus nelfinavir for the initial treatment of HIV infection.

Authors:  Sharon Walmsley; Barry Bernstein; Martin King; José Arribas; Gildon Beall; Peter Ruane; Margaret Johnson; David Johnson; Richard Lalonde; Anthony Japour; Scott Brun; Eugene Sun
Journal:  N Engl J Med       Date:  2002-06-27       Impact factor: 91.245

10.  The risk of Pneumocystis carinii pneumonia among men infected with human immunodeficiency virus type 1. Multicenter AIDS Cohort Study Group.

Authors:  J Phair; A Muñoz; R Detels; R Kaslow; C Rinaldo; A Saah
Journal:  N Engl J Med       Date:  1990-01-18       Impact factor: 91.245

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.